Target intelligence / Profile preview

Dedicator of cytokinesis protein 7 (DOCK7)

Target
DOCK7
Molecular classification
Guanine nucleotide exchange factor (GEF), Member of DOCK-C subfamily in DOCK family, Rho-family GTPase activator, Cytoskeleton regulator
01

Overview

Dedicator of cytokinesis protein 7 (DOCK7) is an atypical guanine nucleotide exchange factor that activates Rac1 and Rac3 GTPases by facilitating GDP-GTP exchange, distinct from canonical GEFs by its DHR2 domain. It plays critical roles in neuronal development—including axon formation and polarization, radial glial cell fate, and signal transduction—and is essential for normal muscle fusion and regeneration via cytoskeletal rearrangement. Pathogenic variants of DOCK7 cause severe neurodevelopmental disorders such as developmental and epileptic encephalopathy 23, with manifestations including epilepsy, intellectual disability, muscle hypotonia, and cortical blindness. DOCK7 is viewed as a high-potential therapeutic target, especially for conditions with impaired Rac1 pathway activation or cytoskeletal dysfunction.

Other names
KIAA1771ZIR2Q96N67 (UniProt)Q00M63Q2PPY7Q45RE8Q45RE9Q5T1B9Q5T1C0Q6ZV32Q8TB82Q96NG6Q96NI0Q9C092
02

Mechanism of action

Small molecules could inhibit or modulate DOCK7’s GEF activity, blocking Rac1/Rac3 activation; PI3K pathway modulation may affect Dock7 recruitment and downstream effects.

03

Biological functions

Axon formation and neuronal polarizationCortical neurogenesis and differentiation of radial glial cellsSignal transduction via Rac1 and Rac3 activationMuscle fusion, regeneration, and structure maintenanceRegulation of septin-actin cytoskeleton interactionsPigmentation regulationPossibly cell motility and phagocytosis (as with other DOCKs)
04

Disease associations

Developmental and epileptic encephalopathy 23 (DEE23)Muscle hypotonia (human pathogenic variants)Intellectual disability and developmental delay (loss-of-function variants)Cortical blindness (in DEE23)Potential modifier of Duchenne muscular dystrophy pathology (via muscle upregulation)
05

Safety considerations

Targeting DOCK7 may affect neuronal development and muscle structure/functionOff-target effects in Rac1/Rac3 and cytoskeletal regulation pathwaysPotential risks for developmental and cognitive outcomes if perturbed in children
06

Interacting drugs

No specific drugs currently approved for DOCK7, but it is a candidate for small molecule ligand discovery and modulation.

1 more in the full profile.

07

Biomarkers

DOCK7 upregulation in muscle biopsies from DMD patientsPathogenic DOCK7 variants associated with DEE23 and muscle hypotonia

Beyond the preview

Go deeper on Dedicator of cytokinesis protein 7 (DOCK7).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicator of cytokinesis protein 7 (DOCK7).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call